Detalhe da pesquisa
1.
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Am J Hematol
; 93(5): 607-614, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29352732
2.
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
Invest New Drugs
; 30(1): 273-81, 2012 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-20740300
3.
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Lancet Oncol
; 12(11): 1004-12, 2011 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-21933749
4.
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol
; 13(10): 1539-1548, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29966800
5.
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
J Clin Oncol
; 34(24): 2858-65, 2016 08 20.
Artigo
Inglês
| MEDLINE | ID: mdl-27022118
6.
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
J Clin Oncol
; 33(17): 1881-8, 2015 Jun 10.
Artigo
Inglês
| MEDLINE | ID: mdl-25624436
7.
Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial.
Am Heart J
; 145(1): 179-86, 2003 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-12514672
8.
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Cancer Chemother Pharmacol
; 70(1): 103-12, 2012 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-22644797
9.
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
J Clin Oncol
; 30(17): 2070-8, 2012 Jun 10.
Artigo
Inglês
| MEDLINE | ID: mdl-22564989
10.
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Lung Cancer
; 74(3): 474-80, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-21680048
11.
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.
Clin Cancer Res
; 16(8): 2450-7, 2010 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-20332327
12.
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
J Clin Oncol
; 26(4): 650-6, 2008 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18235126